Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
PSNL Stock Forecast 2026-2027
$15.79
Current Price
$1.57B
Market Cap
Buy 6
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to PSNL Price Targets
-17.7%
To High Target of $13.00
-30.3%
To Median Target of $11.00
-36.7%
To Low Target of $10.00
PSNL Price Momentum
+12.2%
1 Week Change
+61.9%
1 Month Change
+143.7%
1 Year Change
+98.4%
Year-to-Date Change
-2.2%
From 52W High of $16.15
+311.2%
From 52W Low of $3.84
📊 TOP ANALYST CALLS
Did PSNL Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Personalis is one of their latest high-conviction picks.
Latest PSNL Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, PSNL has a bullish consensus with a median price target of $11.00 (ranging from $10.00 to $13.00). The overall analyst rating is Strong Buy (9.1/10). Currently trading at $15.79, the median forecast implies a -30.3% downside. This outlook is supported by 6 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Tejas Savant at Morgan Stanley, projecting a 17.7% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PSNL Analyst Ratings
6
Buy
1
Hold
0
Sell
PSNL Price Target Range
Low
$10.00
Average
$11.00
High
$13.00
Current: $15.79
Latest PSNL Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PSNL.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jul 9, 2026 | Morgan Stanley | Tejas Savant | Equal-Weight | Maintains | $13.00 |
| May 12, 2026 | Morgan Stanley | Equal-Weight | Maintains | $N/A | |
| May 11, 2026 | BTIG | Buy | Maintains | $N/A | |
| Mar 5, 2026 | Morgan Stanley | Equal-Weight | Maintains | $N/A | |
| Feb 27, 2026 | Needham | Buy | Maintains | $N/A | |
| Feb 11, 2026 | BTIG | Buy | Maintains | $N/A | |
| Jan 26, 2026 | Guggenheim | Buy | Maintains | $N/A | |
| Jan 9, 2026 | BTIG | Buy | Reiterates | $N/A | |
| Dec 2, 2025 | Morgan Stanley | Equal-Weight | Maintains | $N/A | |
| Nov 11, 2025 | Morgan Stanley | Equal-Weight | Maintains | $N/A | |
| Nov 11, 2025 | Guggenheim | Buy | Maintains | $N/A | |
| Nov 11, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Nov 11, 2025 | BTIG | Buy | Maintains | $N/A | |
| Nov 6, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Nov 5, 2025 | Needham | Buy | Maintains | $N/A | |
| Oct 22, 2025 | BTIG | Buy | Maintains | $N/A | |
| Sep 8, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Aug 6, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| May 7, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Apr 10, 2025 | Needham | Buy | Reiterates | $N/A |
Personalis Inc. (PSNL) Competitors
The following stocks are similar to Personalis based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
PSNL
Personalis
mkt cap
1.47B
Personalis Inc. (PSNL) Financial Data
Personalis Inc. has a market capitalization of $1.57B with a P/E ratio of -16.5x. The company generates $64.52M in trailing twelve-month revenue with a -148.1% profit margin.
Revenue growth is -24.9% quarter-over-quarter, while maintaining an operating margin of -207.9% and return on equity of -41.4%.
Valuation Metrics
Market Cap
$1.57B
Enterprise Value
$1.38B
P/E Ratio
-16.5x
PEG Ratio
-0.3x
Price/Sales
24.4x
Growth & Margins
Revenue Growth (YoY)
-24.9%
Gross Margin
+1.8%
Operating Margin
-207.9%
Net Margin
-148.1%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+14.1%
Current Ratio
6.6x
Debt/Equity
15.2x
ROE
-41.4%
ROA
-21.4%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Personalis Inc. (PSNL) Business Model
About Personalis Inc.
What They Do
Advanced genomics services for precision medicine.
Business Model
The company generates revenue by offering a comprehensive platform that integrates genomic data generation with bioinformatics services. By collaborating with research institutions, biopharmaceutical companies, and healthcare providers, Personalis provides critical insights for clinical and academic research, which aids in the development of targeted therapies and personalized treatments.
Additional Information
Headquartered in Menlo Park, California, Personalis Inc. is actively contributing to innovations in personalized healthcare and precision diagnostics, focusing particularly on cancer genomics and the immune response.
Company Information
Sector
Healthcare
Industry
Diagnostics & Research
Employees
259
CEO
Mr. Christopher M. Hall
Country
United States
IPO Year
2019
Website
www.personalis.comPersonalis Inc. (PSNL) Latest News & Analysis
Latest News
Quick Summary
Personalis, Inc. (Nasdaq: PSNL) secured UKCA marking for its NeXT Personal Dx test, allowing clinical use of its Minimal Residual Disease detection technology in Great Britain.
Why It Matters
The UKCA marking for Personalis' NeXT Personal Dx test expands its market access in Great Britain, potentially boosting sales and enhancing its competitive position in precision oncology.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Personalis, Inc. (Nasdaq: PSNL) announced its EDTA and cfDNA Blood Collection Kits received Class A CE-IVD marking, allowing usage in clinical trials across the EU and Great Britain.
Why It Matters
The CE Mark enables Personalis to expand its market in the EU and UK, potentially increasing revenue and investor confidence in its growth prospects in precision oncology.
Source: Business Wire
Market Sentiment:
Neutral
Personalis CEO Sells 100,000 Company Shares Worth $1.1 Million. What Does That Mean for Investors?
1 month ago
Quick Summary
CEO Christopher Hall sold 100,000 shares on May 28-29, 2026, for ~$1.10 million at ~$11.02 per share, following an option exercise; no indirect holdings were involved.
Why It Matters
CEO Christopher Hall's sale of 100,000 shares may signal a lack of confidence in the company's future, potentially impacting investor sentiment and stock price.
Source: The Motley Fool
Market Sentiment:
Neutral
Quick Summary
Personalis, Inc. (Nasdaq: PSNL) presented clinical data at the 2026 ASCO Annual Meeting, highlighting the significance of ultrasensitive MRD detection in six solid tumor types, including colorectal and lung cancers.
Why It Matters
Personalis, Inc.'s positive clinical data on ultrasensitive MRD detection enhances its value proposition in oncology, potentially driving stock performance and investor interest.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Personalis, Inc. is rated Buy due to strong NeXT Personal Dx MRD test momentum and Medicare coverage expansions. Projected 2026 net loss is ~$100m, but test volume is increasing significantly.
Why It Matters
Personalis, Inc.'s Buy rating reflects growth in its diagnostic tests and Medicare coverage, suggesting potential for increased revenue despite projected losses, attracting investor interest.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Personalis, Inc. (Nasdaq: PSNL) will present six clinical abstracts on its NeXT Personal® test at the 2026 ASCO Annual Meeting, including a key presentation from the TRACERx study.
Why It Matters
Personalis's presentation at a major oncology conference highlights its NeXT Personal® test's clinical significance, potentially boosting investor confidence and driving stock value.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About PSNL Stock
What is Personalis Inc.'s (PSNL) stock forecast for 2027?
Based on our analysis of 2 Wall Street analysts, Personalis Inc. (PSNL) has a median price target of $11.00. The highest price target is $13.00 and the lowest is $10.00.
Is PSNL stock a good investment in 2027?
According to current analyst ratings, PSNL has 6 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $15.79. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for PSNL stock?
Wall Street analysts predict PSNL stock could reach $11.00 in the next 12 months. This represents a -30.3% decrease from the current price of $15.79. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Personalis Inc.'s business model?
The company generates revenue by offering a comprehensive platform that integrates genomic data generation with bioinformatics services. By collaborating with research institutions, biopharmaceutical companies, and healthcare providers, Personalis provides critical insights for clinical and academic research, which aids in the development of targeted therapies and personalized treatments.
What is the highest forecasted price for PSNL Personalis Inc.?
The highest price target for PSNL is $13.00 from Tejas Savant at Morgan Stanley, which represents a -17.7% decrease from the current price of $15.79.
What is the lowest forecasted price for PSNL Personalis Inc.?
The lowest price target for PSNL is $10.00 from at , which represents a -36.7% decrease from the current price of $15.79.
What is the overall PSNL consensus from analysts for Personalis Inc.?
The overall analyst consensus for PSNL is bullish. Out of 2 Wall Street analysts, 6 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $11.00.
How accurate are PSNL stock price projections?
Stock price projections, including those for Personalis Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 16, 2026 1:08 PM UTC